27104-72-9

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
ISOQUINOLINE-1-CARBOXYLIC ACID METHYL ESTER is used as a chemical intermediate for the synthesis of various bioactive compounds. Its unique structure and functional groups make it a valuable building block in the development of new drugs with potential therapeutic applications.
Used in Anti-inflammatory and Analgesic Applications:
ISOQUINOLINE-1-CARBOXYLIC ACID METHYL ESTER is used as a potential therapeutic agent for its anti-inflammatory and analgesic properties. Its ability to modulate inflammatory pathways and alleviate pain makes it a promising candidate for the treatment of various inflammatory and painful conditions.
Used in Cancer Treatment:
ISOQUINOLINE-1-CARBOXYLIC ACID METHYL ESTER is used as a potential anticancer agent. Its biological activities have been studied for their potential to target and inhibit the growth of cancer cells, making it a candidate for further research and development in oncology.
Used in Neurodegenerative Disorder Treatment:
ISOQUINOLINE-1-CARBOXYLIC ACID METHYL ESTER is used as a potential therapeutic agent for the treatment of neurodegenerative disorders. Its potential neuroprotective properties and ability to modulate neurodegenerative pathways make it a candidate for further investigation in the development of treatments for conditions such as Alzheimer's disease and Parkinson's disease.

Upstream product

• 67-56-1 methanol 
• 486-73-7 1-isoquinolinecarboxylic acid 
• 1262842-14-7 C₁₈H₁₉NO₄S 

Downstream Products

• 4444-91-1 methyl 9-hydroxy-10-oxostearate 
• 170486-99-4 1-(1,3-dioxolan-2-yl)-2-benzylisoquinolium bromide 
• 153758-56-6 (1,2,3,4-tetrahydroisoquinolin-1-yl)methanol 
• 4494-18-2 isoquinoline-1-carbaldehyde 
• 66948-16-1 rac-2-(isoquinolin-1-yl)-1-phenylethan-2-ol 
• 27311-63-3 1-Hydroxymethyl-isoquinoline 
• 406192-81-2 isoquinoline hydrazide 

Relevant academic research and scientific papers

TAMEisoquin, a novel tripodal fluorescent zinc sensor with high Zn(II) affinity and Zn(II)/Cd(II) selective fluorescence response: Synthesis, coordination geometry, spectroscopy, and comparative response to biometal ions

Herein we report a novel fluorescent zinc sensor 1,1,1-tris (aminomethylethane)N,N′,N″-(2-methylisoquinoline) (TAMEisoquin), [Zn(TAMEisoquin)]2+ complex and its structural and photophysical studies. TAMEisoquin was obtained from reduction of templated [Ni(TAMEisoquin-trisimine)]2+ complex to give [Ni(TAMEisoquin)]2+, which was subsequently decomposed with excess sodium cyanide to afford TAMEisoquin. A competition reaction between TAMEisoquin and the well-known Zn(II) chelator (N,N,N′, N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) at pH 7.2 indicated a conditional dissociation constant for [Zn(TAMEisoquin)]2+ of Kd = 1.4 × 10-15 M. The affinity of TAMEisoquin for Zn(II) is indicative of a ligand design exploiting ring size, preorganization and chelate effects to potentially detect picomolar and femtomolar zinc concentrations. X-ray crystallographic analysis of [Zn(TAMEisoquin)]2+ showed four unique cations that preferred a distorted octahedral geometry with trigonal twist angles that range between 34(2)° and 43.1(8)°. Moreover, [Zn(TAMEisoquin)]2+ complex showed Zn-N bond distances slightly similar to our previously reported [Zn(TAMEpyr)]2+ complex, being Zn-Nheterocyclic, 2.160(1) ? and Zn-Naliphatic, 2.178(4) ? versus 2.128(2) ? and 2.169(2) ? respectively for [Zn(TAMEpyr)]2+. The addition of Zn(II) to TAMEisoquin displayed 11-fold fluorescence enhancement, selective by comparison to divalent biometal ions and Cd(II) which induces only 16% of the Zn(II) response.

Fluorescence “On-Off” chemical sensor for ultrasensitive detection of Al3+ in live cell

An efficient fluorescent probe, 3, 3-bis(4-hydroxyphenyl)-2-benzofuran-1-one-isoquinoline-1-carbohydrazide hydrazine (L), has been prepared for the selective sensing of Al3+ in DMSO-H2O (90:10, v/v) solution. The 1:2 stoichiometry of

A chromone hydrazide Schiff base fluorescence probe with high selectivity and sensitivity for the detection and discrimination of human serum albumin (HSA) and bovine serum albumin (BSA)

The discrimination and identification of human serum albumin (HSA) and bovine serum albumin (BSA) is very important, which is due to the vital roles of two SAs in biological and pharmaceutical research. Based on structural screening and docking calculation from a series of homologues, a coumarin Schiff base fluorescent probe 3-hydroxy-N′-((4-oxo-4H-chromen-3-yl)methylene)-2-naphthohydrazide (HCNH) has been designed and synthesized, which could effectively discriminate HSA and BSA. The probe HCNH exhibited superior sensitivity toward HSA and BSA with the detection limits of 10.62 nM and 16.03 nM in PBS solution, respectively. The binding mechanism of HCNH with SAs was studied by Job's plot analysis, SA destruction and displacement assay. Molecular docking and DFT methods were utilized to provide deep insight into the spatial conformation change of HCNH and binding sites in HSA/BSA. The conformation of HCNH was significantly influenced by the microenvironment provided by HSA and BSA, therefore its fluorescence emission was affected correspondingly. Non-toxic probe HCNH could be successfully used for fluorescence bio-imaging of HSA in cancer cells, which is significantly different from normal cells and favors the application in medical diagnosis.

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

A dual-functional fluorescent probe for sequential determination of Cu2+/S2? and its applications in biological systems

A new acylhydrazine-derived Schiff base fluorescence probe DMI based on “ON-OFF-ON” fluorescence strategy was presented in this paper. Probe DMI could detect Cu2+ selectively and sensitively with dramatic fluorescence quenching in CH3OH-PBS (v/v = 3:7) mixed solution. Once the complex DMI-Cu2+ interacted with S2?, 10.67-folds fluorescence increase was induced via a displacement mechanism under the same experimental conditions. The corresponding detection limits for Cu2+ and S2? were calculated to be 1.52 × 10?8 M and 1.79 × 10?8 M, respectively. The structures of DMI and DMI-Cu2+ were systematically characterized by Job's plot analysis, ESI-MS, IR, X-ray diffraction and density functional theory calculations. Furthermore, fluorescence imaging in MCF-7 cells and zebrafish demonstrated the probe DMI could act as a useful tool to monitor and track intracellular Cu2+ and S2?, which was encouraged by remarkable fluorescence performance and low cytotoxicity. Importantly, the complex DMI-Cu2+ could be applied to detect corrupt blood samples, which could estimate the time of death.

Phenolphthalein Schiff base fluorescent probe and preparation method and application thereof

The invention discloses a phenolphthalein Schiff base fluorescent probe and a preparation method and application thereof, and relates to the field of fluorescent molecular probes. The phenolphthaleinSchiff base fluorescent probe is used for identifying Al

Kinetic Modeling of the Nickel-Catalyzed Esterification of Amides

Nickel-catalyzed coupling reactions provide exciting tools in chemical synthesis. However, most methodologies in this area require high catalyst loadings, which commonly range from 10-20 mol % nickel. Through an academic-industrial collaboration, we demonstrate that kinetic modeling can be used strategically to overcome this problem, specifically within the context of the Ni-catalyzed conversion of amides to esters. The successful application of this methodology to a multigram-scale coupling, using only 0.4 mol % Ni, highlights the impact of this endeavor.

Conversion of amides to esters by the nickel-catalysed activation of amide C-N bonds

Amides are common functional groups that have been studied for more than a century. They are the key building blocks of proteins and are present in a broad range of other natural and synthetic compounds. Amides are known to be poor electrophiles, which is typically attributed to the resonance stability of the amide bond. Although amides can readily be cleaved by enzymes such as proteases, it is difficult to selectively break the carbon-nitrogen bond of an amide using synthetic chemistry. Here we demonstrate that amide carbon-nitrogen bonds can be activated and cleaved using nickel catalysts. We use this methodology to convert amides to esters, which is a challenging and underdeveloped transformation. The reaction methodology proceeds under exceptionally mild reaction conditions, and avoids the use of a large excess of an alcohol nucleophile. Density functional theory calculations provide insight into the thermodynamics and catalytic cycle of the amide-to-ester transformation. Our results provide a way to harness amide functional groups as synthetic building blocks and are expected to lead to the further use of amides in the construction of carbon-heteroatom or carbon-carbon bonds using non-precious-metal catalysis.

PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES

Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.